Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 18, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,165,761	1,959,952	2,245,705	902,290	1,077,892	1,919,220
Market Cap Growth	23.44%	-12.72%	148.89%	-16.29%	-43.84%	3.31%
Enterprise Value	2,155,179	1,934,197	2,185,410	836,710	991,822	1,831,333
Last Close Price	42650.00	38650.00	44300.00	17800.00	21050.00	37500.00
PE Ratio	937.43	-	640.06	3588.03	121.16	97.10
Forward PE	299.55	117.15	261.09	112.30	65.12	88.99
PS Ratio	14.06	14.11	16.65	8.20	10.61	21.66
PB Ratio	13.74	11.64	12.06	5.36	6.59	10.59
P/TBV Ratio	22.53	11.96	12.18	5.43	6.68	10.74
P/FCF Ratio	173.66	253.93	82.47	40.22	-	-
P/OCF Ratio	156.17	209.40	75.76	35.71	1283.40	2065.25
PEG Ratio	-	19.09	19.09	19.09	19.09	30.69
EV/Sales Ratio	13.99	13.92	16.20	7.61	9.76	20.67
EV/EBITDA Ratio	294.08	577.20	437.93	183.55	77.34	207.41
EV/EBIT Ratio	-	8392.22	1253.51	555.66	98.21	308.56
EV/FCF Ratio	172.82	250.60	80.26	37.30	-	-
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.01	0.00
Debt / EBITDA Ratio	0.18	0.43	0.26	0.29	0.10	0.06
Debt / FCF Ratio	0.11	0.19	0.05	0.06	-	-
Asset Turnover	0.74	0.61	0.60	0.53	0.49	0.43
Inventory Turnover	1.95	1.88	2.08	2.11	2.05	2.26
Quick Ratio	0.82	1.29	2.10	2.97	4.35	4.61
Current Ratio	2.01	2.46	3.02	3.92	5.37	5.61
Return on Equity (ROE)	1.40%	-1.02%	1.98%	0.15%	5.16%	12.29%
Return on Assets (ROA)	1.16%	0.06%	0.48%	0.46%	3.02%	1.80%
Return on Capital (ROIC)	1.45%	0.08%	0.61%	0.56%	3.64%	2.30%
Return on Capital Employed (ROCE)	2.30%	0.10%	0.90%	0.80%	5.70%	3.00%
Earnings Yield	0.11%	-0.09%	0.16%	0.03%	0.83%	1.03%
FCF Yield	0.58%	0.39%	1.21%	2.49%	-0.35%	-0.08%
Buyback Yield / Dilution	-0.14%	-0.04%	0.24%	0.76%	-0.05%	-0.00%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.